[go: up one dir, main page]

SG10201912847QA - Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor - Google Patents

Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor

Info

Publication number
SG10201912847QA
SG10201912847QA SG10201912847QA SG10201912847QA SG10201912847QA SG 10201912847Q A SG10201912847Q A SG 10201912847QA SG 10201912847Q A SG10201912847Q A SG 10201912847QA SG 10201912847Q A SG10201912847Q A SG 10201912847QA SG 10201912847Q A SG10201912847Q A SG 10201912847QA
Authority
SG
Singapore
Prior art keywords
combined treatment
tlr7 agonist
capsid assembly
hbv capsid
assembly inhibitor
Prior art date
Application number
SG10201912847QA
Other languages
English (en)
Inventor
Lue Dai
Lu Gao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG10201912847QA publication Critical patent/SG10201912847QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10201912847QA 2015-03-16 2016-03-15 Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor SG10201912847QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2015074269 2015-03-16
CN2015074854 2015-03-23
CN2015084480 2015-07-20
CN2016074012 2016-02-18

Publications (1)

Publication Number Publication Date
SG10201912847QA true SG10201912847QA (en) 2020-02-27

Family

ID=55587263

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912847QA SG10201912847QA (en) 2015-03-16 2016-03-15 Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
SG11201706835WA SG11201706835WA (en) 2015-03-16 2016-03-15 Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201706835WA SG11201706835WA (en) 2015-03-16 2016-03-15 Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor

Country Status (27)

Country Link
US (1) US11771699B2 (fr)
EP (3) EP3270915B1 (fr)
JP (3) JP6667547B2 (fr)
KR (4) KR20220020412A (fr)
CN (1) CN107427514B (fr)
AU (3) AU2016232353B2 (fr)
CA (1) CA2979490C (fr)
CL (1) CL2017002230A1 (fr)
CR (1) CR20170424A (fr)
DK (1) DK3270915T3 (fr)
ES (1) ES2798598T3 (fr)
HK (1) HK1245082A1 (fr)
HR (1) HRP20200943T1 (fr)
HU (1) HUE050736T2 (fr)
IL (3) IL253493B (fr)
MA (2) MA52701A (fr)
MX (2) MX370769B (fr)
MY (1) MY190603A (fr)
PE (2) PE20171648A1 (fr)
PL (1) PL3270915T3 (fr)
PT (1) PT3270915T (fr)
RS (1) RS60350B1 (fr)
RU (1) RU2718917C2 (fr)
SG (2) SG10201912847QA (fr)
SI (1) SI3270915T1 (fr)
UA (1) UA123670C2 (fr)
WO (1) WO2016146598A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3114128B1 (fr) * 2014-03-07 2019-01-02 F. Hoffmann-La Roche AG Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b
MA41134B1 (fr) 2014-12-08 2021-03-31 Hoffmann La Roche Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
PL3270915T3 (pl) 2015-03-16 2020-08-24 F. Hoffmann-La Roche Ag Leczenie skojarzone z zastosowaniem agonisty tlr7 i inhibitora składania kapsydu hbv
EP4001283A1 (fr) * 2015-05-12 2022-05-25 F. Hoffmann-La Roche AG Aminothiazolopyrimidinedione substituée pour le traitement et la prophylaxie d'une infection virale
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
WO2017211791A1 (fr) * 2016-06-07 2017-12-14 F. Hoffmann-La Roche Ag Polythérapie à base d'un inhibiteur de hbsag et d'un agoniste de tlr7
JP7101663B2 (ja) * 2016-09-13 2022-07-15 エフ．ホフマン－ラ ロシュ アーゲー Ｔｌｒ７アゴニストとｈｂｖキャプシドアセンブリ阻害剤の併用療法
CN110139868B (zh) * 2017-01-06 2021-07-09 豪夫迈·罗氏有限公司 制备3-取代的5-氨基-6H-噻唑并[4,5-d]嘧啶-2,7-二酮化合物的方法
EP3565819A2 (fr) * 2017-01-06 2019-11-13 H. Hoffnabb-La Roche Ag Nouvelles formes solides de [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tétrahydrofuran-2-yl]propyl]acétate
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
JP7260488B2 (ja) 2017-06-26 2023-04-18 サンシャイン・レイク・ファーマ・カンパニー・リミテッド ジヒドロピリミジン化合物、及び医薬におけるその使用
AU2018291688B2 (en) 2017-06-27 2022-02-03 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
WO2019076310A1 (fr) * 2017-10-18 2019-04-25 Sunshine Lake Pharma Co., Ltd. Composés dihydropyrimidine et utilisations de ceux-ci en médecine
AU2018361364B2 (en) 2017-11-02 2020-11-26 Aicuris Gmbh & Co. Kg Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV)
US11236087B2 (en) 2017-11-02 2022-02-01 Aicuris Gmbh & Co. Kg Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV)
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
AR116948A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
UY38437A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
AR116947A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
EP3873913A1 (fr) 2018-11-02 2021-09-08 AiCuris GmbH & Co. KG Nouvelles urée-6,7-dihydro-4 h-thiazolo[5,4-c]pyridines actives contre le virus de l'hépatite b (vhb)
UY38434A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
UY38439A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
EP3894004A1 (fr) * 2018-12-14 2021-10-20 F. Hoffmann-La Roche AG Dérivés de chroman-4-one pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
TW202035412A (zh) * 2018-12-20 2020-10-01 比利時商健生藥品公司 雜芳基二氫嘧啶衍生物和治療ｂ型肝炎感染之方法
MA54560A (fr) * 2018-12-20 2021-10-27 Janssen Pharmaceutica Nv Dérivés d'hétéroaryldihydropyrimidine et procédés de traitement d'infections par le virus de l'hépatite b
CN113614088A (zh) 2019-03-25 2021-11-05 豪夫迈·罗氏有限公司 Hbv核心蛋白变构修饰剂化合物的固体形式
MX2021013105A (es) 2019-04-30 2021-11-17 Aicuris Gmbh & Co Kg Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb).
MX2021013085A (es) 2019-04-30 2021-11-17 Aicuris Gmbh & Co Kg Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb).
KR20220002498A (ko) 2019-04-30 2022-01-06 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 대해 활성인 신규 인돌리진-2-카르복스아미드
JP2022531199A (ja) 2019-04-30 2022-07-06 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｂ型肝炎ウイルス（ｈｂｖ）に対し活性な新規のフェニル及びピリジル尿素
EP3980419A1 (fr) 2019-06-06 2022-04-13 F. Hoffmann-La Roche AG Procédé de rechange pour la préparation d'acide 4-phényl-5-alcoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]méthyl]-3-oxo-5,6,8,8a-tétrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylique
CA3140702A1 (fr) * 2019-06-18 2020-12-24 Helen Horton Combinaison de vaccins contre le virus de l'hepatite b (vhb) et de derives de dihydropyrimidine en tant que modulateurs d'assemblage de capside
WO2021018237A1 (fr) * 2019-07-31 2021-02-04 Janssen Sciences Ireland Unlimited Company Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
CR20220282A (es) * 2019-11-26 2022-11-28 Primmune Therapeutics Inc Agonistas del tlr7
CN114846140A (zh) * 2019-12-24 2022-08-02 豪夫迈·罗氏有限公司 用于治疗hbv的靶向hbv的治疗性寡核苷酸和tlr7激动剂的药物组合
KR20220119616A (ko) * 2019-12-24 2022-08-30 에프. 호프만-라 로슈 아게 Tlr7 효현제를 이용하여 바이러스 감염을 치료하는 방법
CA3174304A1 (fr) 2020-04-02 2021-10-07 Ashish Kumar Pathak Nouveaux analogues de la 2-pyrimidone utilises comme agents antiviraux puissants contre les alphavirus
CA3190794A1 (fr) 2020-08-05 2022-02-10 Soren Ottosen Traitement par oligonucleotides des patients atteints d'hepatite b
CN114621219A (zh) * 2020-12-09 2022-06-14 上海维申医药有限公司 一种二氢嘧啶类化合物、其制备方法及应用
CN118165920B (zh) * 2024-05-14 2024-08-06 内蒙古大学 一种Tlr7&8双激动剂小鼠性控分选液和使用方法及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5166141A (en) 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
SI20024A (sl) 1996-10-16 2000-02-29 Icn Pharmaceuticals, Inc. Purinovi L-nukleozidi, analogi in uporaba od teh
EP1072607A3 (fr) 1996-10-16 2001-09-12 ICN Pharmaceuticals, Inc. Analogues de nucléosides-L-purine et leurs utilisations
DE10012549A1 (de) 2000-03-15 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012824A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
WO2005016235A2 (fr) 2003-04-14 2005-02-24 The Regents Of The University Of California Utilisation combinee d'inhibiteurs de l'inosine monophosphate deshydrogenase (impdh) et d'agonistes du toll-like recepteur
JP2007503268A (ja) 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
ATE465742T1 (de) 2003-09-05 2010-05-15 Anadys Pharmaceuticals Inc Tlr7-liganden zur behandlung von hepatitis c
MXPA06003351A (es) * 2003-10-01 2006-06-08 Altana Pharma Ag Derivados de imidazopiridina como inhibidores de no-sintasa inducible.
WO2005085462A1 (fr) 2004-02-27 2005-09-15 Dsm Ip Assets B.V. Preparation enzymatique d'un aminoacide beta-2 enrichi de maniere enantiomere
US20070129320A9 (en) 2004-07-18 2007-06-07 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
WO2006033995A2 (fr) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidine-4-ones possedant une activite antihepatite b
JP2006088985A (ja) * 2004-09-27 2006-04-06 Toyoda Gosei Co Ltd 頭部保護エアバッグ装置
WO2006054129A1 (fr) 2004-11-19 2006-05-26 Institut Gustave Roussy Traitement ameliore du cancer par arn double brin
CN101212968B (zh) * 2004-12-17 2011-11-16 安那迪斯药品股份有限公司 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
DK2561872T3 (en) * 2004-12-17 2014-12-08 Anadys Pharmaceuticals Inc 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED 3H-OXAZOLO- [4,5-d] PYRIMIDIN-2-ON COMPOUNDS AND PRODRUGS THEREOF
BRPI0616378A2 (pt) 2005-09-22 2011-06-21 Scripps Research Inst inibidores de proteìna cinase baseados em alcóxi indolinona e métodos para modulação da atividade catalìtica
AU2006311462A1 (en) 2005-11-09 2007-05-18 Cheng Si Yuan (China-International) Hepatitis Research Foundation Diagnostic and therapeutic methods and agents
CL2007001427A1 (es) 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
WO2007143582A2 (fr) 2006-06-05 2007-12-13 Baylor College Of Medicine Inversion de la fonction supressive de lymphocytes t spécifiques par le signal du récepteur 8 de type toll
TWI418561B (zh) * 2006-06-22 2013-12-11 Anadys Pharmaceuticals Inc ５-胺基-３-（３’-去氧-β-Ｄ-核糖呋喃糖基（ｒｉｂｏｆｕｒａｎｏｓｙｌ））-噻唑并〔４，５-ｄ〕嘧啶-２，７-二酮之前藥
ATE499940T1 (de) 2006-07-18 2011-03-15 Anadys Pharmaceuticals Inc Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
BRPI0717741A2 (pt) 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
US20110166092A1 (en) * 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
WO2009067547A1 (fr) 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase de type polo
PL2098526T3 (pl) 2008-02-22 2014-06-30 Neurotune Ag Bicykliczne związki zawierające azot aktywne w stanach przewlekłego bólu
DE102008027648A1 (de) 2008-06-10 2009-12-17 Schaeffler Kg Spannvorrichtung
CA2735177C (fr) 2008-08-29 2014-03-25 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Derives heterocycliques bicycliques satures en tant qu'antagonistes de smo
WO2010069147A1 (fr) 2008-12-17 2010-06-24 张中能 Derives de la dihydropyrimidine, leurs compositions et leur utilisation
CN102372706A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2012088414A1 (fr) 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Formulation liposomale de céramides non-glycosidiques et leurs utilisations
WO2013052844A1 (fr) 2011-10-07 2013-04-11 Pulmatrix, Inc. Méthodes pour le traitement et le diagnostic d'infections des voies respiratoires
EP3312160B1 (fr) * 2011-12-21 2020-03-18 Novira Therapeutics Inc. Agents antiviraux de l'hépatite b
AU2013305390C1 (en) * 2012-08-24 2015-12-24 Ruyuan Wei Xiang Technology Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
MX2015002954A (es) * 2012-09-10 2015-06-05 Hoffmann La Roche Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b.
WO2014165128A2 (fr) * 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Agents antiviraux contre l'hépatite b
EP2997032B1 (fr) * 2013-05-17 2018-07-25 F.Hoffmann-La Roche Ag Héteroaryldihydropyrimidines pontées en position 6 pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
CN104650069B (zh) 2013-11-19 2019-04-19 广东东阳光药业有限公司 4-甲基二氢嘧啶类化合物及其在药物中的应用
WO2015127409A1 (fr) * 2014-02-21 2015-08-27 Vibrant Holdings, Llc Photo-activation sélective d'acides aminés pour un couplage peptidique en une seule étape
EP3114128B1 (fr) * 2014-03-07 2019-01-02 F. Hoffmann-La Roche AG Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b
WO2015172128A1 (fr) 2014-05-09 2015-11-12 Indiana University Research And Technology Corporation Méthodes et compositions pour traiter les infections par le virus de l'hépatite b
MA41134B1 (fr) * 2014-12-08 2021-03-31 Hoffmann La Roche Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
PL3270915T3 (pl) 2015-03-16 2020-08-24 F. Hoffmann-La Roche Ag Leczenie skojarzone z zastosowaniem agonisty tlr7 i inhibitora składania kapsydu hbv
EP3370759A1 (fr) * 2015-11-03 2018-09-12 H. Hoffnabb-La Roche Ag Polythérapie au moyen d'un inhibiteur d'ensemble capside hbv et d'un interféron
JP7101663B2 (ja) 2016-09-13 2022-07-15 エフ．ホフマン－ラ ロシュ アーゲー Ｔｌｒ７アゴニストとｈｂｖキャプシドアセンブリ阻害剤の併用療法

Also Published As

Publication number Publication date
NZ733805A (en) 2021-04-30
JP2021100967A (ja) 2021-07-08
KR102359212B1 (ko) 2022-02-08
PT3270915T (pt) 2020-06-17
JP6859468B2 (ja) 2021-04-14
RU2017135467A (ru) 2019-04-17
JP2018508552A (ja) 2018-03-29
WO2016146598A1 (fr) 2016-09-22
MX2017011488A (es) 2018-01-23
IL253493B (en) 2020-11-30
MX370769B (es) 2019-12-20
JP7195360B2 (ja) 2022-12-23
US11771699B2 (en) 2023-10-03
BR112017019758A2 (pt) 2018-05-29
CR20170424A (es) 2018-01-26
EP3270915A1 (fr) 2018-01-24
HUE050736T2 (hu) 2021-01-28
AU2019202966A1 (en) 2019-05-16
IL282706A (en) 2021-06-30
IL276865B (en) 2021-05-31
MY190603A (en) 2022-04-27
EP3695837C0 (fr) 2024-11-20
SG11201706835WA (en) 2017-09-28
UA123670C2 (uk) 2021-05-12
PL3270915T3 (pl) 2020-08-24
US20180000824A1 (en) 2018-01-04
CN107427514B (zh) 2021-07-13
SI3270915T1 (sl) 2020-07-31
CN107427514A (zh) 2017-12-01
DK3270915T3 (da) 2020-06-15
KR102139708B1 (ko) 2020-07-31
EP3845227A1 (fr) 2021-07-07
IL276865A (en) 2020-10-29
PE20171648A1 (es) 2017-11-13
EP3695837B1 (fr) 2024-11-20
JP2020100637A (ja) 2020-07-02
KR20190085185A (ko) 2019-07-17
EP3695837A1 (fr) 2020-08-19
AU2021202122A1 (en) 2021-05-06
PE20211647A1 (es) 2021-08-24
MA52701A (fr) 2021-03-31
MX2022011756A (es) 2022-10-07
MA55581A (fr) 2022-02-16
HRP20200943T1 (hr) 2020-09-18
AU2016232353B2 (en) 2019-05-16
KR20220020412A (ko) 2022-02-18
KR20200091505A (ko) 2020-07-30
CA2979490C (fr) 2023-07-18
AU2019202966B2 (en) 2021-04-15
RU2718917C2 (ru) 2020-04-15
RS60350B1 (sr) 2020-07-31
JP6667547B2 (ja) 2020-03-18
CL2017002230A1 (es) 2018-04-13
EP3270915B1 (fr) 2020-04-15
HK1245082A1 (zh) 2018-08-24
CA2979490A1 (fr) 2016-09-22
RU2017135467A3 (fr) 2019-09-10
IL253493A0 (en) 2017-09-28
ES2798598T3 (es) 2020-12-11
KR20170113658A (ko) 2017-10-12
AU2016232353A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
IL282706A (en) Combined treatment with TLR7 agonist and HBV capsid assembly inhibitor
IL287545A (en) Combined treatment with tlr7 agonist and hbv capsid assembly inhibitor
HK1250236A1 (zh) 用gdf8抑制劑增加力量和功能的方法
HK1255463A1 (zh) Hbv衣殼組裝抑制劑和干擾素的組合療法
ZA201804070B (en) Eif4-a-inhibiting compounds and methods related thereto
IL262378A (en) Compositions and methods containing a capsid assembly inhibitor
HK1252200A1 (zh) 針及相關組件和方法
IL280863A (en) Ototaxin inhibitors and their uses
HK1254830A1 (zh) 工程化植酸酶及其使用方法
GB201413355D0 (en) Compositons and methods
GB201522349D0 (en) An assembly and a method of using the assembly
SG11201706615WA (en) Methods and apparatuses for pushing a message
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
GB201609584D0 (en) A de-oiler and a method of using the same
GB201515194D0 (en) Nappy and insert therefor
IL251162A0 (en) Monoamine oxidase-B inhibitors and rehabilitation
LT3270915T (lt) Kombinuotasis gydymas tlr7 agonistu ir hbv kapsidės surinkimo inhibitoriumi
GB2548916B (en) Muzzle and headcollar
GB201521499D0 (en) Logo of a bull body
GB201508711D0 (en) Grip and cue rite
GB201500724D0 (en) Lowry tattoo gun
GB201415141D0 (en) An evacuation assembly and arrangement
PL2927551T3 (pl) Tuleja łącząca oraz szafka rozdzielcza